Skip to main content
. Author manuscript; available in PMC: 2021 Jun 30.
Published in final edited form as: Circulation. 2019 Mar 18;139(22):2594–2596. doi: 10.1161/CIRCULATIONAHA.118.039180

Figure 1.

Figure 1.

Study consort diagram (A), and specific reasons for cardiovascular disease exclusion within pivotal cancer trials (B).

Abbreviations: BP, blood pressure; CAD, coronary artery disease; CVA, cerebrovascular accident; CVD, cardiovascular disease; ECG, electrocardiogram; HTN, hypertension; GI, gastrointestinal; VTE, venous thromboembolic disease.

*Several therapies were approved on the basis of breakthrough phase II data, with ongoing or as yet to be initiated phase III trials.

†The percentages reported reflect a denominator of 64 (the total number of trials with exclusion of cardiovascular disease patients).

‡CAD, includes myocardial infarction.

§Usually defined as >150/90 mmHg, consistent with mild (ie. stage 1) hypertension by the available contemporary guidelines.

∥Other CVD included valvular disease, myocarditis, or other mention of cardiovascular disease.